HIGHLIGHTS
- who: BCG-Mediated Bladder Cancer Immunotherapy and collaborators from the Department of Urology, University Hospital of Basel, University of Basel, Basel, Switzerland, Unité d'Immunologie des Cellules Dendritiques, Institut Pasteur, Paris have published the research: BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model, in the Journal: PLOS ONE | www.plosone.org of February/25,/2013
- what: The authors provide insight into relevant clinical questions using a novel mathematical model of the model predicts an altered regimen that may decrease side effects of treatment while improving response to therapy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.